Comparative Pharmacology
Head-to-head clinical analysis: SULFA TRIPLE 2 versus SULFALAR.
Peer-Reviewed Evidence
Head-to-head clinical analysis: SULFA TRIPLE 2 versus SULFALAR.
SULFA-TRIPLE #2 vs SULFALAR
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
The sulfonamides (sulfamethazine, sulfathiazole, sulfamerazine) act as competitive inhibitors of para-aminobenzoic acid (PABA) utilization in bacterial dihydrofolate synthesis, thereby inhibiting folic acid synthesis and bacterial growth.
Sulfamethoxazole is a sulfonamide that competitively inhibits dihydropteroate synthase, blocking folic acid synthesis; trimethoprim inhibits dihydrofolate reductase, producing sequential blockade of folic acid metabolism in bacteria.
2 tablets orally every 4 hours initially, then 2 tablets every 6 hours thereafter. Each tablet contains 167 mg sulfadiazine, 167 mg sulfamerazine, and 167 mg sulfamethazine (total sulfonamide 500 mg per tablet).
Oral: 500 mg to 1 g every 12 hours; extended-release: 1 g every 12 hours. Intravenous: 1 g every 12 hours.
None Documented
None Documented
Sulfadiazine: 10-16 hours; Sulfamerazine: 15-24 hours; Sulfamethazine: 12-24 hours. The combined half-life is approximately 15-20 hours in patients with normal renal function, requiring dosing every 12-24 hours.
Terminal elimination half-life: 7-12 hours (prolonged in renal impairment up to 24-48 hours; clinical context: dosing interval adjustment needed for CrCl <30 mL/min)
Renal (approximately 70-80% as unchanged sulfonamides via glomerular filtration and tubular secretion); biliary/fecal (approximately 20-30% as metabolites).
Renal: approximately 70-80% as unchanged drug and acetylated metabolite; biliary/fecal: 20-30%
Category C
Category C
Antibiotic (Sulfonamide)
Antibiotic (Sulfonamide)